Composition with effects of maintaining blood glucose health level and protecting peripheral nerves

Abstract

The invention discloses a composition with the effects of maintaining the healthy level of blood sugar and protecting peripheral nerves, specifically, the composition comprises a white kidney bean extract and at least one component selected from resistant dextrin and a mulberry leaf extract, the mass ratio of the resistant dextrin to the white kidney bean extract is (1.5-6): 1, and the content of the mulberry leaf extract in the white kidney bean extract is (1.5-6): 1. The mass ratio of the white kidney bean extract to the mulberry leaf extract is (1.5-2): 1; in terms of dry matter weight, in the composition, the concentration of the resistant dextrin is 0.00-0.90 g / g, the concentration of the white kidney bean extract is 0.10-0.70 g / g, and the concentration of the mulberry leaf extract is 0.00-0.40 g / g. The composition has the effects of maintaining the healthy level of blood sugar and protecting peripheral nerves.

Description

Technical Field

[0001] This invention belongs to the field of food, especially functional food or pharmaceuticals, and specifically relates to compositions that have the effects of maintaining healthy blood sugar levels and protecting peripheral nerves. Background Technology

[0002] With changing lifestyles and an aging population, the incidence of diabetes is rising year by year, becoming a major public health problem worldwide. Diabetes is characterized by persistent hyperglycemia, and long-term hyperglycemia can lead to damage to multiple organs and systems in the body. Among these, peripheral neuropathy is one of the most common chronic complications of diabetes.

[0003] Currently, commonly used medications for diabetes include insulin, metformin, and sulfonylureas. However, long-term use of these drugs may be accompanied by adverse reactions such as hypoglycemia and gastrointestinal issues. Furthermore, simple blood sugar-lowering therapy is often insufficient to effectively prevent or reverse the progression of peripheral neuropathy. Existing treatments for diabetic peripheral neuropathy primarily focus on neurotrophic agents and improved microcirculation; however, the efficacy of these methods varies among individuals, and the overall treatment effect is limited.

[0004] Therefore, developing a composition that can both help lower blood sugar levels and effectively protect peripheral nerves, delaying or improving neuropathy, is of great significance for improving the quality of life of diabetic patients. Summary of the Invention

[0005] To address the shortcomings of existing technologies, the present invention adopts the following technical solution:

[0006] The present invention provides a composition comprising white kidney bean extract and at least one component selected from resistant dextrin and mulberry leaf extract, wherein the mass ratio of resistant dextrin to white kidney bean extract is 1.5 to 6:1, and the mass ratio of white kidney bean extract to mulberry leaf extract is 1.5 to 2:1; based on dry matter weight, the composition contains 0.00 to 0.90 g / g of resistant dextrin, 0.10 to 0.70 g / g of white kidney bean extract, and 0.00 to 0.40 g / g of mulberry leaf extract.

[0007] In some embodiments, the concentration of resistant dextrin in the composition is 0.40 to 0.90 g / g, based on dry matter weight.

[0008] In some embodiments, the concentration of mulberry leaf extract in the composition is 0.30–0.40 g / g, based on dry matter weight.

[0009] In some embodiments, the composition comprises white kidney bean extract and resistant dextrin, wherein the mass ratio of resistant dextrin to white kidney bean extract is 2.5–6:1. As a preferred embodiment, the concentration of white kidney bean extract is 0.10–0.30 g / g and the concentration of resistant dextrin is 0.70–0.90 g / g, based on dry matter weight.

[0010] Resistant dextrin is a dietary fiber, and mulberry leaf extract is a plant extract. Both share similar mechanisms of action in lowering blood sugar, namely, inhibiting the digestion and absorption of carbohydrates in the intestines. In the intestines, resistant dextrin binds with water to form a gel-like substance that effectively prevents the diffusion of sugars and the breakdown of sugars by digestive enzymes in the small intestine. 1-Deoxynojirimycin (DNJ) in mulberry leaves is a natural α-glucosidase inhibitor that can delay the breakdown of carbohydrates in the intestines.

[0011] In some embodiments, the white kidney bean extract is a white to beige powder with an activity (AAIU / g) ≥ 2250, moisture content ≤ 10%, and a mesh size (through US 60 mesh) ≥ 99%.

[0012] In some embodiments, the white kidney bean extract contains, in the following proportions of solids: white kidney bean accounts for more than 90%, and gum arabic accounts for less than 10%.

[0013] In some embodiments, the resistant dextrin contains ≥82g / 100g of total dietary fiber. As a preferred embodiment, the resistant dextrin contains 96.39g / 100g of total dietary fiber.

[0014] In some embodiments, the particle size (passing rate, 80 mesh) of the mulberry leaf extract is 100%.

[0015] In some embodiments, the mulberry leaf extract contains 1.3% 1-deoxynojirimycin (DNJ) chloric acid and its salt (calculated as chlorate).

[0016] In some embodiments, the composition further includes oat beta-glucan.

[0017] In some embodiments, the fineness (80 mesh) of the oat β-glucan is ≥95%, and the β-glucan content is ≥70.0 g / 100 g.

[0018] As a preferred embodiment, the mass ratio of resistant dextrin, white kidney bean extract, and oat β-glucan is 1.5–2:1:1;

[0019] As a preferred embodiment, the concentration of the resistant dextrin is 0.40-0.50 g / g, the concentration of the oat β-glucan is 0.20-0.30 g / g, and the concentration of the white kidney bean extract is 0.20-0.30 g / g, based on dry matter weight.

[0020] In some embodiments, the composition includes white kidney bean extract and mulberry leaf extract, wherein the concentration of white kidney bean extract is 0.60-0.70 g / g and the concentration of mulberry leaf extract is 0.30-0.40 g / g, based on dry matter weight.

[0021] In another aspect, the present invention provides a food product containing the aforementioned composition.

[0022] In some implementations, the food is selected from dairy products, beverages, pasta products, condiments, and meat products.

[0023] In some implementation schemes, the food is described as a health food.

[0024] In some embodiments, the dairy product is milk powder. As a preferred embodiment, the milk powder contains 1.30–14.00 g / 100g of resistant dextrin, 0.60–2.00 g / 100g of oat β-glucan, 0.60–2.70 g / 100g of white kidney bean extract, and 0.50–1.60 g / 100g of mulberry leaf extract.

[0025] In some embodiments, the concentration of resistant dextrin in the milk powder is 6.00–14.00 g / 100 g, preferably 6.00–12.00 g / 100 g.

[0026] In some embodiments, the concentration of the white kidney bean extract in the milk powder is 2.00–8.00 g / 100 g.

[0027] In some embodiments, the concentration of resistant dextrin in the milk powder is 1.30–1.70 g / 100 g.

[0028] In some embodiments, the concentration of oat β-glucan in the milk powder is 0.60–2.00 g / 100 g.

[0029] In some embodiments, the concentration of the white kidney bean extract in the milk powder is 0.60–0.70 g / 100 g.

[0030] In some embodiments, the concentration of the white kidney bean extract in the milk powder is 1.00–1.50 g / 100 g.

[0031] The present invention also provides the use of the aforementioned compositions or the aforementioned foods in the preparation of products that help maintain healthy blood sugar levels.

[0032] In some implementations, the product also has a peripheral nerve protection effect.

[0033] In some implementations, the product can be used as an adjunct therapy for type 2 diabetes.

[0034] In some implementations, the product can be used to improve pancreatic islet inflammation / immune response.

[0035] In some implementations, the contribution to maintaining healthy blood sugar levels includes inhibiting the expression of the jak2b and il6st genes.

[0036] In some implementations, the method of helping to maintain healthy blood sugar levels also includes suppressing the expression of the jak1 and stat3 genes.

[0037] In some implementations, the benefits of maintaining healthy blood sugar levels also include promoting the expression of the socs3a gene.

[0038] Jak2b primarily affects pancreatic islet inflammation / immune response; it is associated with il6st, jak1, stat3, socs3a, and type II diabetes.

[0039] In some implementation schemes, the product is a pharmaceutical or health food.

[0040] Beneficial effects:

[0041] The compositions of this invention help maintain healthy blood sugar levels. The compositions of this invention also offer cost reduction benefits.

[0042] The composition of the present invention also has peripheral nerve protection effects and synergistic effects. Attached Figure Description

[0043] Figure 1 Typical fluorescence intensity of peripheral nerves in zebrafish after treatment with the sample (resistant dextrin + oat β-glucan + white kidney bean extract);

[0044] Figure 2 Typical fluorescence intensity of peripheral nerves in zebrafish after treatment with samples (mulberry leaves + white kidney beans). Detailed Implementation

[0045] Before further describing specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terminology used in the embodiments of the present invention is for describing specific embodiments and not for limiting the scope of protection of the present invention.

[0046] When numerical ranges are given in the embodiments, it should be understood that, unless otherwise stated in the present invention, both endpoints of each numerical range and any value between the two endpoints may be selected. Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art. In addition to the specific methods, apparatus, and materials used in the embodiments, based on the knowledge of the prior art possessed by one of ordinary skill in the art and the description of this invention, any prior art methods, apparatus, and materials similar to or equivalent to those described, apparatus, and materials in the embodiments of this invention may be used to implement the present invention.

[0047] Unless otherwise stated, the experimental methods, detection methods, and preparation methods not described in detail in this invention all adopt conventional techniques in this technical field.

[0048] Example

[0049] 1. Testing materials

[0050] 1.1 Sample Preparation Information

[0051] Resistant dextrin (Resistant dextrin type 90), Baolingbao Biotechnology Co., Ltd. Prepare a 20.0 mg / mL stock solution using standard dilution water; prepare fresh before use.

[0052] White kidney bean extract (produced by Pharmachem Corporation of the United States using a natural, standardized, water extraction process from the North American native white kidney bean variety (Phaseolus vulgaris), PRODUCT CODE: 1WHI00350P), Shanghai Tongyuan Food Technology Co., Ltd. Prepare a 10.0 mg / mL stock solution with standard dilution water; prepare fresh before use.

[0053] Oat β-glucan (SF-HOG70), Guangzhou Zhongkang Food Co., Ltd. Prepare a 2.00 mg / mL stock solution using standard dilution water, homogenize by sonication, and prepare fresh before use.

[0054] Mulberry leaf extract (Disugar) TM Mulberry leaf extract, Disugar TM Morus alba L. Extract), Guangdong Qingyunshan Pharmaceutical Co., Ltd. Prepare a 20.0 mg / mL stock solution using standard dilution water; prepare fresh before use.

[0055] Positive control: Pioglitazone Hydrochloride Tablets, white tablets, batch number 20220503, Jiangsu Deyuan Pharmaceutical Co., Ltd., store in a cool place away from light. Prepare a stock solution of 10.0 mg / mL with ddH2O and store at -20°C.

[0056] Sitagliptin Phosphate Tablets (hereinafter referred to as sitagliptin), white tablets, batch number U035871, Merck Sharp & Dohme Italia SPA, store in a cool place away from light. Prepare a stock solution of 3.50 mg / mL with ultrapure water and use immediately after preparation.

[0057] 1.2 Experimental animals

[0058] Zebrafish were all raised in fish culture water at 28°C (water quality: add 200 mg of instant sea salt to every 1 L of reverse osmosis water, conductivity is 450 - 550 μS / cm; pH is 6.5 - 8.5; hardness is 50 - 100 mg / L CaCO3), provided by the fish breeding center of Hangzhou Huante Biotechnology Co., Ltd., and the experimental animal use license number is: SYXK(Zhe)2022 - 0004. The feeding management meets the requirements of international AAALAC certification (certification number: 001458).

[0059] Wild - type AB strain zebrafish, reproduced by natural paired mating. Zebrafish at 5 days post - fertilization (5 dpf) were used for the maximum test concentration (MTC) of samples and the efficacy test for helping to maintain healthy blood glucose levels.

[0060] Transgenic peripheral nerve green fluorescent zebrafish (NBT strain), reproduced by natural paired mating. Zebrafish at 5 dpf were used for the study of the efficacy of peripheral nerve protection.

[0061] 1.3 Instruments, consumables and reagents

[0062] Dissecting microscope (SZX7, OLYMPUS, Japan); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); Precision electronic balance (CP214, OHAUS, USA); Blood glucose meter (ACCU-CHEK Performa, Roche Diagnostics Products (Shanghai) Co., Ltd., China); High-speed centrifuge (TG16G, Shanghai Yihe Biotechnology Co., Ltd., China); Ultrasonic cleaner (JP-010T, Shenzhen Jiemeng Cleaning Equipment Co., Ltd., China); Fully automatic sample grinder (JXFSTPRP-24L, Shanghai Jingxin Laboratory Equipment Technology Department, China); Homogenizer (T10, IKA, Germany); Conventional PCR amplification instrument (T100, BIO-RAD, Singapore); Real-time PCR instrument (CFX Connect, BIO-RAD, Singapore); High-speed refrigerated centrifuge (Heraeus). Fresco 17 (Thermo Fisher, Germany); UV-Vis spectrophotometer (Nanodrop 2000, Thermo, USA); Microplate mini centrifuge (BE-6100, Haimen Qilin Bell Instrument Manufacturing Co., Ltd., China); Low-skirted 96-well plate (transparent) (HSP9601, Bio-rad, USA); Optical adhesive sealing film B (MSB1001, Bio-rad, USA); Fully automatic sample grinder (JXFSTPRP-24L, Shanghai Jingxin Experimental Equipment Technology Department, China).

[0063] Pure egg yolk powder (batch number 20200809, Zhejiang Agribusiness Biotechnology Co., Ltd., China); D-(+)-glucose (batch number L2108079, Shanghai Aladdin Biochemical Technology Co., Ltd., China); anhydrous ethanol (batch number 20210901, Sinopharm Chemical Reagent Co., Ltd., China); blood glucose meter test strips (batch number 478829, Roche Diagnostics Products (Shanghai) Co., Ltd., China); iTaq Universal SYBR Green Supermix (catalog number 1725124, Bio-rad, USA); FastKing cDNA first strand synthesis kit (genomically degenerated) (catalog number KR116-02, Tiangen Biotech (Beijing) Co., Ltd., China); RNA-Quick Purification Kit (catalog number RN001, Shanghai Yishan Biotechnology Co., Ltd., China).

[0064] 2. Detection Method

[0065] 2.1 Evaluation of efficacy in maintaining healthy blood sugar levels

[0066] Wild-type AB strain zebrafish (5 dpf) were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker (experimental group). Water-soluble samples (concentrations shown in Tables 1, 4, and 7) were administered, along with a positive control of pioglitazone hydrochloride at a concentration of 20.0 μg / mL. A normal control group and a model control group were also established. Each beaker had a volume of 25 mL. Except for the normal control group, the other experimental groups were given a 0.15% egg yolk powder solution during the day and a 3% glucose solution at night to establish a zebrafish hyperglycemia model. After treatment at 28℃ for 48 h, the zebrafish were washed three times with fish tank water. The overall glucose level of the zebrafish was measured using a glucometer. The glucose level was analyzed and statistically analyzed to evaluate the efficacy of the sample in maintaining healthy blood glucose levels. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS 26.0 software; p < 0.05 indicated statistical significance.

[0067] 2.2 Peripheral nerve protective effect

[0068] 30 zebrafish of the 5dpf NBT strain were randomly selected and placed in beakers. The test sample was administered in aqueous solution, with sitagliptin at a concentration of 350 μg / mL as a positive control. A normal control group and a model control group were also included. Each beaker contained 25 mL of fluid. Except for the normal control group, the other experimental groups were administered 0.15% egg yolk powder solution during the day and 3% glucose solution at night to establish a zebrafish hyperglycemia model. After treatment at 28℃ for 96 h, 10 zebrafish from each experimental group were randomly selected and photographed under a fluorescence microscope. Data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software. The fluorescence intensity of zebrafish nerves was analyzed, and the statistical analysis results were used to evaluate the peripheral neuroprotective efficacy of the test substance. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS 26.0 software; p < 0.05 indicated statistical significance.

[0069] 2.3 Research on mechanisms that help maintain healthy blood glucose levels (genes)

[0070] Wild-type AB strain zebrafish (5 dpf) were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker (experimental group). Water-soluble samples (concentrations shown in Tables 3 and 6) were administered, along with a positive control of pioglitazone hydrochloride at a concentration of 20.0 μg / mL. A normal control group and a model control group were also established. Each beaker had a volume of 25 mL. Except for the normal control group, the other experimental groups were given a 0.15% egg yolk powder solution during the day and a 3% glucose solution at night to establish a zebrafish hyperglycemia model. Three biological replicates were performed. After treatment at 28℃ for 48 h, total RNA was extracted from the zebrafish in each group using the RNA-Quick Purification Kit, and the concentration and purity of total RNA were determined using a UV-Vis spectrophotometer. Total RNA from 2.00 μg zebrafish samples was collected, and 20.0 μL of cDNA was synthesized according to the instructions of the cDNA first-strand synthesis kit. The expression of β-actin and the genes jak1, jak2b, stat3, il6st, and socs3a was detected by q-PCR. β-actin was used as an internal control for gene expression, and the relative RNA expression levels of jak1, jak2b, stat3, il6st, and socs3a genes were calculated. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS 26.0 software; p < 0.05 was considered statistically significant.

[0071] 3. Experimental Results

[0072] 3.1 Results of the study on the composition of "resistant dextrin + white kidney bean extract"

[0073] 3.1.1 Evaluation of efficacy in maintaining healthy blood sugar levels

[0074] Under the experimental conditions, 1. Resistant dextrin + white kidney bean extract at concentrations of 500 ± 167 μg / mL and 1000 ± 167 μg / mL effectively maintained healthy blood glucose levels; 2. Comparing the same composition, resistant dextrin + white kidney bean extract at a concentration of 500 ± 167 μg / mL was superior to either resistant dextrin or white kidney bean extract alone in maintaining healthy blood glucose levels, demonstrating a synergistic effect; 3. Comparing the same composition, resistant dextrin + white kidney bean extract at a concentration of 1000 ± 167 μg / mL was superior to resistant dextrin alone in maintaining healthy blood glucose levels, and its effect was comparable to that of resistant dextrin alone. Since the raw material price of white kidney bean extract is much higher than that of resistant dextrin, using some resistant dextrin to replace white kidney bean extract can reduce costs while maintaining comparable blood glucose levels. (Resistant dextrin: 22 yuan / kg; white kidney bean extract: 900 yuan / kg)

[0075] The experimental results are shown in Table 1.

[0076] Table 1. Results of the experiment evaluating the efficacy of the samples in maintaining healthy blood glucose levels (n=10)

[0077]

[0078] Compared with the model control group, ***p<0.001.

[0079] Compared with resistant dextrin + white kidney bean extract 1000 + 167 μg / mL, ^^^ p<0.001.

[0080] 3.1.2 Research on mechanisms that help maintain healthy blood glucose levels (genes)

[0081] 3.1.2.1 RNA extraction results and primer sequence information

[0082] After sample processing, total RNA was extracted from zebrafish, and the RNA concentration and A260 / A280 ratio were determined using a UV-Vis spectrophotometer. The A260 / A280 ratios were all between 1.8 and 2.2, indicating that the extracted total RNA from zebrafish was of good quality and suitable for subsequent q-PCR experiments. Primer sequences are shown in Table 2.

[0083] Table 2 Primer sequence information

[0084]

[0085]

[0086] 3.1.2.2 Effects of the sample on blood glucose-related genes

[0087] The JAK / STAT system consists of four JAKs and seven STAT family members. JAKs are a class of non-receptor tyrosine protein kinases (PTKs), while signal transduction and transcription activators (STATs) are cytoplasmic proteins located on chromosomes that bind to the DNA of target gene regulatory regions and are downstream substrates of JAKs. JAK / STATs are widely distributed in various types of tissues and cells, playing a dual role as signal transduction and gene transcription activators. Activation of these proteins can induce various biological effects, including cellular stress, inflammation, growth and development, hematopoiesis, proliferation, differentiation, and apoptosis. In recent years, the JAK / STAT signaling pathway has been shown to play important roles in diabetic nephropathy, diabetic neuropathy and retinopathy, and the formation and function of adipocytes.

[0088] Alterations in muscle mass and skeletal muscle insulin resistance may be early initiating events in type 2 diabetes. JAK / STAT plays a crucial role in adipogenesis, and stat3 silencing can prevent lipid-induced insulin resistance. In diabetes, the expression of jak1, jak2, and stat3 is upregulated, while stat4 expression is downregulated, and socs1 / 3 / 7 are activated, providing negative feedback regulation for other related genes in the JAK / STAT / SOCS pathway. Under high glucose concentrations, overexpression of socs reverses glucose-induced JAK / STAT activation and reduces the destructive effects of β-cytotoxic cytokines in diabetes.

[0089] IL6, as a pro-inflammatory cytokine, activates IL6st, thereby activating the JAK / STAT signaling pathway. IL6st is the β subunit of the IL6 cytokine receptor and is essential for IL6-mediated STAT3 activation and stimulation of glucagon secretion. In type 2 diabetes mellitus with inflammation, IL6st may promote hyperglycemia by stimulating α cells to secrete glucagon.

[0090] Under the experimental conditions, resistant dextrin plus white kidney bean 500 + 167 μg / mL had no regulatory effect on the expression of jak1 and stat3 genes, but it could downregulate the expression of jak2b and il6st genes and upregulate the expression of socs3a gene. The experimental results are shown in Table 3.

[0091] Table 3. Experimental results of the study on the mechanism by which the samples help maintain healthy blood glucose levels (n=3)

[0092]

[0093] Compared with the model control group, *p<0.05, **p<0.01, ***p<0.001.

[0094] 3.2 Results of the study on the composition of "resistant dextrin + oat β-glucan + white kidney bean extract"

[0095] 3.2.1 Evaluation of efficacy in maintaining healthy blood sugar levels

[0096] Under the conditions of this experiment, 1. the combination of resistant dextrin, oat β-glucan, and white kidney bean extract at a concentration of 111 ± 55.6 ± 55.6 μg / mL demonstrated the efficacy of maintaining healthy blood glucose levels; 2. compared to other combinations, the combination of resistant dextrin, oat β-glucan, and white kidney bean extract at a concentration of 111 ± 55.6 ± 55.6 μg / mL was superior to either resistant dextrin or oat β-glucan alone in maintaining healthy blood glucose levels, and its efficacy was comparable to that of white kidney bean extract alone. Since the raw material price of white kidney bean extract is much higher than that of resistant dextrin and oat β-glucan, partially replacing white kidney bean extract with resistant dextrin and oat β-glucan can achieve cost reduction while maintaining comparable efficacy in maintaining healthy blood glucose levels. (Resistant dextrin 22 yuan / kg, oat β-glucan 280 yuan / kg, white kidney bean extract 900 yuan / kg) The experimental results are shown in Table 4.

[0097] Table 4. Results of the experiment evaluating the efficacy of the samples in maintaining healthy blood glucose levels (n=10)

[0098]

[0099]

[0100] Compared with the model control group, ***p<0.001.

[0101] Compared with resistant dextrin + oat β-glucan + white kidney bean extract 111 + 55.6 + 55.6 μg / mL, $ p<0.05, $$ p<0.01.

[0102] 3.2.2 Peripheral nerve protective effect

[0103] Under the experimental conditions, 1. Compared with the model control group, both resistant dextrin + oat β-glucan + white kidney bean extract at concentrations of 111 + 55.6 + 55.6 μg / mL and white kidney bean extract at concentrations of 222 μg / mL exhibited peripheral neuroprotective effects. 2. Compared with the concentration of resistant dextrin + oat β-glucan + white kidney bean extract at concentrations of 111 + 55.6 + 55.6 μg / mL, the peripheral neuroprotective effects of resistant dextrin, oat β-glucan, and white kidney bean extract alone at 222 μg / mL were inferior to those of the combination, demonstrating a synergistic effect among the three. The experimental results are shown in Table 5.

[0104] Table 5. Experimental results of the study on the protective efficacy of the samples against peripheral nerves (n=10)

[0105]

[0106] Compared with the model control group, ***p<0.001.

[0107] Compared with resistant dextrin + oat β-glucan + white kidney bean extract 111 + 55.6 + 55.6 μg / mL, && p<0.01, &&& p<0.001.

[0108] Figure 1 This is a typical fluorescence intensity diagram of the peripheral nerves of zebrafish after sample treatment; Note: The area within the red dashed box is the analysis area.

[0109] 3.2.3 Research on mechanisms that help maintain healthy blood glucose levels (genes)

[0110] Under the experimental conditions, resistant dextrin + oat β-glucan + white kidney bean 111 + 55.6 + 55.6 μg / mL downregulated the expression of jak1, jak2b, stat3, and il6st genes, but had no regulatory effect on the expression of socs3a gene. The experimental results are shown in Table 6.

[0111] Table 6. Results of the study on the mechanism by which the samples help maintain healthy blood glucose levels (n=3)

[0112] Compared with the model control group, *p<0.05, **p<0.01, ***p<0.001.

[0113] 3.3 Research Results of the Combination of "Mulberry Leaf + White Kidney Bean"

[0114] 3.3.1 Evaluation of efficacy in maintaining healthy blood sugar levels

[0115] Under the experimental conditions, 1. the combination of mulberry leaf extract and white kidney bean extract at a concentration of 46.0 ± 83.3 μg / mL demonstrated the efficacy of maintaining healthy blood glucose levels; 2. compared within the same composition, the combination of mulberry leaf extract and white kidney bean extract at a concentration of 46.0 ± 83.3 μg / mL was superior to either mulberry leaf extract or white kidney bean extract alone in maintaining healthy blood glucose levels, proving that the two have a synergistic effect. The experimental results are shown in Table 7.

[0116] Table 7. Results of the experiment evaluating the efficacy of the samples in maintaining healthy blood glucose levels (n=10)

[0117]

[0118] Compared with the model control group, ***p<0.001.

[0119] Compared with mulberry leaf extract + white kidney bean extract (46.0 + 83.3 μg / mL), $$p<0.01, $$$ p<0.001.

[0120] 3.3.2 Peripheral nerve protective effect

[0121] Under the experimental conditions, compared with the model control group, the combination of mulberry leaf extract and white kidney bean extract (46.0 ± 83.3 μg / mL) showed peripheral neuroprotective effects. The experimental results are shown in Table 8.

[0122] Table 8. Experimental results of the study on the protective efficacy of the samples against peripheral nerves (n=10)

[0123]

[0124] Compared with the model control group, ***p<0.001.

[0125] Figure 2 This is a typical fluorescence intensity diagram of the peripheral nerves of zebrafish after sample treatment; Note: The area within the red dashed box is the analysis area.

[0126] The above description of the embodiments is provided to enable those skilled in the art to understand and use the invention. It will be apparent to those skilled in the art that various modifications can be made to these embodiments, and the general principles described herein can be applied to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the invention should be within the protection scope of the present invention.

Claims

1. A composition comprising white kidney bean extract and at least one ingredient selected from resistant dextrin and mulberry leaf extract, wherein, The mass ratio of resistant dextrin to white kidney bean extract is 1.5–6:1, and the mass ratio of white kidney bean extract to mulberry leaf extract is 1.5–2:

1. Based on dry matter weight, the composition contains 0.00–0.90 g / g of resistant dextrin, 0.10–0.70 g / g of white kidney bean extract, and 0.00–0.40 g / g of mulberry leaf extract.

2. The composition according to claim 1, wherein, The concentration of resistant dextrin in the composition, based on dry matter weight, is 0.40–0.90 g / g. Preferably, the composition comprises white kidney bean extract and resistant dextrin, wherein the mass ratio of resistant dextrin to white kidney bean extract is 2.5 to 6:1; preferably, the concentration of white kidney bean extract is 0.10 to 0.30 g / g and the concentration of resistant dextrin is 0.70 to 0.90 g / g, based on dry matter weight.

3. The composition according to claim 1, wherein, The composition also includes oat β-glucan; Preferably, the mass ratio of resistant dextrin, white kidney bean extract, and oat β-glucan is 1.5–2:1:1; Preferably, the concentration of the resistant dextrin is 0.40-0.50 g / g, the concentration of the oat β-glucan is 0.20-0.30 g / g, and the concentration of the white kidney bean extract is 0.20-0.30 g / g, based on dry matter weight.

4. The composition according to claim 1, wherein, The concentration of mulberry leaf extract in the composition, based on dry matter weight, is 0.30–0.40 g / g. Preferably, the composition comprises white kidney bean extract and mulberry leaf extract, wherein the concentration of white kidney bean extract is 0.60-0.70 g / g and the concentration of mulberry leaf extract is 0.30-0.40 g / g, based on dry matter weight.

5. A food product comprising the composition according to any one of claims 1-4.

6. The food product according to claim 5, wherein, The food is selected from dairy products, beverages, flour products, condiments, and meat products; preferably, the food is a health food.

7. The food product according to claim 6, wherein, The dairy product is milk powder. Preferably, in the milk powder, the concentration of resistant dextrin is 1.30-14.00 g / 100 g, the concentration of oat β-glucan is 0.60-2.00 g / 100 g, the concentration of white kidney bean extract is 0.60-8.00 g / 100 g, and the concentration of mulberry leaf extract is 0.50-1.60 g / 100 g.

8. The use of the composition according to any one of claims 1-4 or the food according to any one of claims 5-7 in the preparation of products that help maintain healthy blood sugar levels.

9. The application according to claim 8, wherein, The methods mentioned for maintaining healthy blood sugar levels include inhibiting the expression of the jak2b and il6st genes; Preferably, the method of helping to maintain healthy blood sugar levels also includes inhibiting the expression of the jak1 and stat3 genes; Preferably, the method of helping to maintain healthy blood sugar levels also includes promoting the expression of the socs3a gene.

10. The application according to claim 8 or 9, wherein, The product in question is a pharmaceutical or health food product.

Images